Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Medical Officer | August 19, 2024 | August 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date August 19, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 143,483 |
Reported balance
After 2024-08-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-19 · Sale · Disposed 2,060 · Balance 143,483 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 143,222 |
Reported balance
After 2024-08-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-08-19 · Sale · Disposed 261 · Balance 143,222 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive. F4: Includes 110,408 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive.
F4: Includes 110,408 unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 20, 2024 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 261 | $46.00 | $12,006.00 |
DisclosureSEC source: 0000950170-24-099125 · ownership.xml · nonDerivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,222 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive. F4 · balance_after: Includes 110,408 unvested RSUs. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,060 | $45.01 | $92,720.60 |
DisclosureSEC source: 0000950170-24-099125 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,483 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 23:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,008 | $31.27 | $31,520.16 |
DisclosureSEC source: 0000950170-24-072168 · ownership.xml · nonDerivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,543 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes 115,565 unvested RSUs. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 23:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,628 | $31.27 | $50,907.56 |
DisclosureSEC source: 0000950170-24-072168 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,551 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| May 16, 2024 Filed May 18, 2024 01:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 425 | $28.59 | $12,150.75 |
DisclosureSEC source: 0000950170-24-062079 · ownership.xml · nonDerivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,179 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive. F4 · balance_after: Includes 119,209 unvested RSUs. Read SEC document |
| May 16, 2024 Filed May 18, 2024 01:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,956 | $28.20 | $55,159.20 |
DisclosureSEC source: 0000950170-24-062079 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,604 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 01:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,030 | $25.58 | $26,347.40 |
DisclosureSEC source: 0000950170-24-030483 · ownership.xml · nonDerivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,560 F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.55 to $25.63, inclusive. F3 · balance_after: Includes 124,366 unvested RSUs. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,585 | $25.70 | $40,734.50 |
DisclosureSEC source: 0000950170-24-030483 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,590 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 124,366 unvested RSUs. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:52 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,557 | $26.20 | $40,793.40 |
DisclosureSEC source: 0000950170-24-029609 · ownership.xml · nonDerivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,175 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $26.23, inclusive. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:52 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 8,364 | $25.80 | $215,791.20 |
DisclosureSEC source: 0000950170-24-029609 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,732 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021 and November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.51 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Included 128,010 unvested RSUs. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 407 | $25.00 | $10,175.00 |
DisclosureSEC source: 0000950170-24-022242 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,096 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023. F2 · balance_after: Includes 140,510 unvested RSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,493 | $25.07 | $137,709.51 |
DisclosureSEC source: 0000950170-24-015259 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,503 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 145,667 unvested RSUs. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 100 | $25.00 | $2,500.00 |
DisclosureSEC source: 0000950170-24-008063 · ownership.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,996 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023. F2 · balance_after: Includes 145,667 unvested RSUs. Read SEC document |
| December 12, 2023 Filed Dec 12, 2023 22:33 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 978 | $10.55 | $10,317.90 |
DisclosureSEC source: 0001209191-23-058328 · doc4.xml · nonDerivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,096 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.37 to $10.75, inclusive. F3 · balance_after: Includes 145,667 unvested RSUs. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:33 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,688 | $10.72 | $18,095.36 |
DisclosureSEC source: 0001209191-23-058328 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,074 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 145,667 unvested RSUs. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:29 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 32,131 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001209191-23-055524 · doc4.xml · derivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,131 Underlying: Common Stock · 32,131 shares Expires 2033-11-14 F3 · derivative.exercise_date: This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:29 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 82,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055524 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,762 F1 · shares: Consists of shares of Common Stock issuable under 82,512 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024. F2 · balance_after: Includes 149,311 unvested RSUs. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 23:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,707 | $10.41 | $17,769.87 |
DisclosureSEC source: 0001209191-23-049362 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,250 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.07 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 66,799 unvested RSUs. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 22:40 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,698 | $12.43 | $21,106.14 |
DisclosureSEC source: 0001209191-23-037165 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,957 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 70,443 unvested RSUs. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 7,441 | $13.33 | $99,188.53 |
DisclosureSEC source: 0001209191-23-018979 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,655 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021, December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 74,087 unvested RSUs. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 22:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 628 | $10.87 | $6,826.36 |
DisclosureSEC source: 0001209191-22-060969 · doc4.xml · nonDerivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,096 F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · balance_after: Includes 90,231 unvested RSUs. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 56,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001209191-22-060969 · doc4.xml · derivative · entry 3 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2032-12-08 F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060969 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,724 F1 · shares: Consists of shares of Common Stock issuable under 36,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023. F2 · balance_after: Includes 91,625 unvested RSUs. Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 21:28 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 658 | $14.05 | $9,244.90 |
DisclosureSEC source: 0001209191-22-050123 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,724 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 55,625 unvested RSUs. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 00:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 668 | $4.95 | $3,306.60 |
DisclosureSEC source: 0001209191-22-037145 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,382 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 57,019 unvested RSUs. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 21:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 640 | $8.73 | $5,587.20 |
DisclosureSEC source: 0001209191-22-018533 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,050 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 58,413 unvested RSUs. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 00:22 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,617 | $8.56 | $48,081.52 |
DisclosureSEC source: 0001209191-22-015901 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,690 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 2, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.56 to $8.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 59,807 unvested RSUs. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:21 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 67,935 | $0.00 Strike: $13.12 | $0.00 |
DisclosureSEC source: 0001209191-21-069422 · doc4.xml · derivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,935 Underlying: Common Stock · 67,935 shares Expires 2031-12-09 F3 · derivative.exercise_date: This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:21 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 22,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069422 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,307 F1 · shares: Consists of shares of Common Stock issuable under 22,307 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022. F2 · balance_after: Includes 72,307 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 00:24 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $17.77 | $0.00 |
DisclosureSEC source: 0000899243-21-009963 · doc4.xml · derivative · entry 2 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option was granted on March 2, 2021. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 1, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 00:24 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009963 · doc4.xml · nonDerivative · entry 1 Farwell Wildon · CIK 0001847941 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Consists of shares of Common Stock issuable under 50,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on March 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.